Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Nov 17, 2023 12:31pm
131 Views
Post# 35741327

RE:RE:RE:RE:RE:RE:RE:Institutional investor

RE:RE:RE:RE:RE:RE:RE:Institutional investor

Regarding due diligence on potent share aquiring fund(s)?
First, people need to resd both sides of the ledger.
Anson, is a multi- avenue mutual fund.
yes, they do include shorting. They also have main focus as long term brad based mutual fund investments.
They took on a 7%-8% investment of Onc ( Canadian TSX shares only). In the event the get to exercise thier warrants ( part of purchase agreement), that would put them very close to 10% holders if the company.
By far the largest institutional investor.
They certainly are not going to short their own shares & would benefit greatly from an increase, to be able to benifit from the warrants.
I guess the question would be , why would Onc not want Anson?
On a much wider view , most mutual funds carry in their descriptions the ability to short.
The real question worth discussion? Why did Anson take such a large position?
countless FUDsters touted " zero institutional investment". For many quarters.
Which BTW was never true. The number has ally's been low 1%-2% , but not zero.
Now with Ansons addition, the total woukd be above 10%.
There are those who have insights to the potential.
Yes, I agree 100%,: things need to change & very soon.
 

<< Previous
Bullboard Posts
Next >>